The bidding war between Pfizer ( PFE) and Novo Nordisk ( NVO) over obesity drug developer Metsera ( MTSR) finally ended over ...

Novo Nordisk (NYSE:NVO) climbs about 2% on Monday afternoon after it says it will not raise its offer for Metsera ...

Equity markets delivered a mixed response after Pfizer won the bidding war for anti-obesity drugmaker Metsera, as Metsera’s ...

Novo Nordisk A/S posted solid revenue and profit increases, with a resilient pipeline and strong dividend yield. Learn more ...

On November 4, 2025, just a day after Pfizer filed its suits against Novo Nordisk and Metsera, Novo Nordisk submitted an ...

Metsera stock was tumbling on Monday after Pfizer agreed to buy the weight-loss drug start-up in a deal that could end up ...

Metsera, the US biotech with a pipeline of next-generation metabolic hormone weight loss drugs, has agreed a sale to Pfizer ...

Pfizer wins the $10B bid for Metsera, opening new avenues for obesity treatment and addressing unmet healthcare needs with ...

As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...

Late Friday, after a dramatic bidding war, he learned he’d finally claimed his prize. Bourla found out at around 9 p.m. that ...

At a price of up to $10 billion, Pfizer has claimed victory in its bidding war against Novo Nordisk to acquire Metsera. It's ...

Dems accept shutdown deal without ACA guarantee; RFK Jr. wades into menopause treatment fray; Novo shares rise despite loss ...